Dr. Reddy’s Laboratories Limited (NYSE: RDY) is -12.58% lower on its value in year-to-date trading and has touched a low of $47.88 and a high of $73.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RDY stock was last observed hovering at around $57.32 in the last trading session, with the day’s loss setting it -0.14% off its average median price target of $63.59 for the next 12 months. It is also 29.14% off the consensus price target high of $80.70 offered by 35 analysts, but current levels are -1.2% lower than the price target low of $56.50 for the same period.
Currently trading at $57.18, the stock is 3.05% and 5.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.15 million and changing -0.24% at the moment leaves the stock -1.57% off its SMA200. RDY registered -21.17% loss for a year compared to 6-month loss of -9.42%. The firm has a 50-day simple moving average (SMA 50) of $54.29 and a 200-day simple moving average (SMA200) of $58.05.
The stock witnessed a 3.38% gain in the last 1 month and extending the period to 3 months gives it a 1.73%, and is 2.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.78% over the week and 1.53% over the month.
Dr. Reddy’s Laboratories Limited (RDY) has around 24795 employees, a market worth around $9.53B and $2.68B in sales. Current P/E ratio is 32.23 and Fwd P/E is 18.60. Profit margin for the company is 11.00%. Distance from 52-week low is 19.42% and -22.03% from its 52-week high. The company has generated returns on investments over the last 12 months (9.20%).
Dr. Reddy’s Laboratories Limited (RDY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Dr. Reddy’s Laboratories Limited (RDY) is a “Buy”. 35 analysts offering their recommendations for the stock have an average rating of 1.50, where 4 rate it as a Hold and 5 think it is a “Overweight”. 26 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Dr. Reddy’s Laboratories Limited is expected to release its quarterly report on 10/28/2022.The EPS is expected to grow by 36.70% this year.
Dr. Reddy’s Laboratories Limited (RDY) Top Institutional Holders
The shares outstanding are 165.95M, and float is at 117.35M with Short Float at 1.11%.
Dr. Reddy’s Laboratories Limited (RDY): Who are the competitors?
The company’s main competitors (and peers) include Sanofi (SNY) that is -1.49% lower over the past 12 months. Pfizer Inc. (PFE) is 29.08% up on the 1-year trading charts. Short interest in the company’s stock has fallen -37.82% from the last report on Apr 28, 2022 to stand at a total of 1.37 million short shares sold with a short interest ratio of 6.31.